TipRanks
Advertisement
Advertisement
Orchestra BioMed upgraded to Buy from Neutral at BTIG
PremiumThe FlyOrchestra BioMed upgraded to Buy from Neutral at BTIG
21d ago
Orchestra BioMed Highlights Pivotal Cardiovascular Program Progress
Premium
Company Announcements
Orchestra BioMed Highlights Pivotal Cardiovascular Program Progress
23d ago
Orchestra BioMed price target raised to $10 from $9 at Piper Sandler
Premium
The Fly
Orchestra BioMed price target raised to $10 from $9 at Piper Sandler
2M ago
Orchestra BioMed price target raised to $13 from $12 at Barclays
PremiumThe FlyOrchestra BioMed price target raised to $13 from $12 at Barclays
5M ago
Orchestra BioMed reports Q1 EPS (33c), consensus (44c)
Premium
The Fly
Orchestra BioMed reports Q1 EPS (33c), consensus (44c)
5M ago
Orchestra BioMed gives clinical, regulatory update on BACKBEAT trial timeline
Premium
The Fly
Orchestra BioMed gives clinical, regulatory update on BACKBEAT trial timeline
5M ago
Orchestra BioMed reports FY25 EPS ($1.11), consensus ($1.74)
PremiumThe FlyOrchestra BioMed reports FY25 EPS ($1.11), consensus ($1.74)
7M ago
Orchestra BioMed: Undervalued Cardiovascular Innovator Poised for Multi‑Year Catalyst Cycle
Premium
Ratings
Orchestra BioMed: Undervalued Cardiovascular Innovator Poised for Multi‑Year Catalyst Cycle
7M ago
Orchestra BioMed management to meet with B. Riley
Premium
The Fly
Orchestra BioMed management to meet with B. Riley
7M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―